X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Everest Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Under the agreement, Everest will develop and commercialize KZR-616 (zetomipzomib), Kezar’s novel, first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea and Southeast Asia.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: $132.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2023
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
KZR-616 (zetomipzomib), a first-in-class inhibitor of the immunoproteasome, has potent anti-inflammatory effects. Zetomipzomib continued to be well-tolerated over the course of the 37-week study, demonstrating a favorable safety and tolerability profile.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
The MISSION Phase 2 topline results show a clinically meaningful overall renal response to KZR-616 (zetomipzomib) after 6 months, without high-dose induction therapy. Patients in the trial also experienced reductions in extra-renal manifestations of lupus.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
KZR-616 (zetomipzomib) demonstrated a favorable safety and tolerability profile, including in the PRESIDIO Open-label Extension Study where weekly zetomipzomib has been administered for up to an additional 77 weeks.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN).
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Proceeds from the transaction will be used for general growth capital and for further advancement of the Company’s clinical candidates, KZR-616 and KZR-261.
Lead Product(s): Zetomipzomib
Therapeutic Area: Musculoskeletal Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
